Action Genmab AS - GMAB

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

20,31

Prix Achat

20,06

Prix Vente

20,60

Volume échangé

1 808 290

20,13 Fourchette du Jour 20,43

0,00 Plage de 52 semaines 0,00

Cap du marché

13,42B

Clôture Veille

20,09

Ouverture

20,17

Dernière Transaction

20.31

Dernière heure de transaction

Volume financier

US$ 36 714 526

VWAP

20,3035

Volume moyen (3 m)

Actions en circulation

660 745 350

Rendement du Dividende

Ratio Cours sur Bénéfices

31,81

Bénéfice par action (BPA)

6,59

Chiffre d'affairess

16,47B

Bénéfice net

4,35B

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the stan... Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered wth Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications. Show more

Secteur

Biological Pds,ex Diagnstics

Industrie

Biogenetic (human)

Site Web

www.genmab.com

Siège social

Copenhagen, Dnk

Fondé

2000

Genmab AS est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker GMAB. Le dernier cours de clôture d'Genmab AS était de US$20,09. Au cours de la dernière année, les actions de Genmab AS ont été négociées dans une fourchette de prix de US$ 0,00 à US$ 0,00.

Genmab AS compte actuellement 660 745 350 actions en circulation. La capitalisation boursière d'Genmab AS est de US$13,27 milliard. Genmab AS a un ratio cours/bénéfice (ratio PE) de 31.81.

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Results from Arm 1 of the EPCORE® NHL-2 trial show treatment with epcoritamab combination led to an overall response rate (ORR) of 100 percent and a complete response (CR) rate of 87 percent in...

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Genmab A/S (Nasdaq: GMAB): Preliminary analyses from the EPCORE® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily...

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Genmab A/S (Nasdaq: GMAB): Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent 21-month progression-free survival (PFS) in patients with...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Genmab A/S (Nasdaq: GMAB): More than 20 abstracts, including four oral presentations, with new clinical data across lines of therapy and subgroups of non-Hodgkin’s lymphoma (NHL) patients New...

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion cohort Responses with Rina-S were observed...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

GMAB - Frequently Asked Questions (FAQ)

What is the current Genmab AS share price?

The current share price of Genmab AS is US$ 20,31

How many Genmab AS shares are in issue?

Genmab AS has 660 745 350 shares in issue

What is the market cap of Genmab AS?

The market capitalisation of Genmab AS is USD 13,27B

What is the 1 year trading range for Genmab AS share price?

Genmab AS has traded in the range of US$ 0,00 to US$ 0,00 during the past year

What is the PE ratio of Genmab AS?

The price to earnings ratio of Genmab AS is 31,81

What is the cash to sales ratio of Genmab AS?

The cash to sales ratio of Genmab AS is 8,4

What is the reporting currency for Genmab AS?

Genmab AS reports financial results in DKK

What is the latest annual turnover for Genmab AS?

The latest annual turnover of Genmab AS is DKK 16,47B

What is the latest annual profit for Genmab AS?

The latest annual profit of Genmab AS is DKK 4,35B

What is the registered address of Genmab AS?

The registered address for Genmab AS is KALVEBOD BRYGGE 43, COPENHAGEN, 1260

What is the Genmab AS website address?

The website address for Genmab AS is www.genmab.com

Which industry sector does Genmab AS operate in?

Genmab AS operates in the BIOGENETIC (HUMAN) sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
MYSZMy Size Inc	US$ 4,2001 (211,12%)	120,01M
NVNINVNI Group Ltd	US$ 8,26 (209,36%)	76,64M
TPICTPI Composites Inc	US$ 2,45 (100,82%)	33,95M
ICGIntchains Group Ltd	US$ 8,77 (88,60%)	527,61k
HSDTHelius Medical Technologies Inc	US$ 0,884851 (84,34%)	120,4M
CYNCYNGN Inc	US$ 0,4603 (-71,41%)	27,5M
MTEMMolecular Templates Inc	US$ 0,1502 (-57,09%)	8,63M
PRFXPainReform Ltd	US$ 5,15 (-53,85%)	2,84M
GALTGalectin Therapeutics Inc	US$ 1,03 (-48,50%)	8,58M
BCABBioAtla Inc	US$ 0,6923 (-41,82%)	5,96M
EDBLEdible Garden AG Inc	US$ 0,24 (65,06%)	354,33M
NVDANVIDIA Corporation	US$ 134,70 (3,08%)	310,19M
APTOAptose Biosciences Inc	US$ 0,28 (64,51%)	306,25M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0,606999 (6,49%)	293,22M
PLTRPalantir Technologies Inc	US$ 80,55 (8,54%)	281,23M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Genmab AS (GMAB)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Genmab AS

GMAB Dernières nouvelles

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

GMAB - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Genmab AS (GMAB) Cours

Genmab AS (GMAB)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Genmab AS

GMAB Dernières nouvelles

GMAB - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR